Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K14/165

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/139631AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY AND/OR PREVENTION OF SARS-COV-2-RELATED INFECTION
WO 30.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2021/050447 Applicant JOINT STOCK COMPANY "BIOCAD" Inventor GERSHOVICH, Pavel Mikhailovich
The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated codon-optimized nucleic acid encoding an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to an expression cassette and a vector based thereon, as well as to an AAV5 (adeno-associated virus serotype 5)-based recombinant virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.
2.WO/2022/135563METHOD FOR SIMULTANEOUSLY INDUCING IMMUNE RESPONSE AGAINST MULTIPLE VIRUSES
WO 30.06.2022
Int.Class C07K 14/11
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
11Orthomyxoviridae, e.g. influenza virus
Appl.No PCT/CN2021/141198 Applicant SHANGHAI PUBLIC HEALTH CLINICAL CENTER Inventor XU, Jianqing
Provided is a method for simultaneously inducing an immune response against multiple viruses (such as influenza viruses and novel coronavirus). Provided is an immunogenic peptide including: (a) an immunogenic stem including an HA2 region of influenza virus hemagglutinin HA; (b) an immunogenic crown including a viral membrane protein or an immunogenic fragment thereof; and (c) optionally, other portions fused to the above-mentioned portions, wherein the virus from which the viral membrane protein is derived is different from the virus from which the HA2 region in (a) is derived.
3.202092658ВАКЦИНА ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ КОРОНАВИРУСНОЙ ИНФЕКЦИИ
EA 30.06.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202092658 Applicant ДУХОВЛИНОВ ИЛЬЯ ВЛАДИМИРОВИЧ Inventor Духовлинов Илья Владимирович

Изобретение относится к молекулярной биологии, биотехнологии, медицине и может быть использовано для осуществления профилактики и лечения коронавирусной инфекции, главным образом, вызываемой 2019-nCoV. Предложена вакцина на основе генетической конструкции, кодирующей гибридный белок, включающий фрагменты белков M, S, N, E нового коронавируса, а также в одном из вариантов дополнительно содержащая такой гибридный белок. Преимущества разработанной вакцины - быстрота и простота получения (от 2-3 ч); безопасность, за счет природы действующего вещества, а также отсутствия полного сайта связывания с ACE2 у синтезируемого с генетической конструкцией гибридного белка, отсутствия его гомологии с белками организма; индукция профиля иммунного ответа, в немалой степени представленного цитотоксическим иммунным ответом, помимо гуморального; отсутствие затруднения диагностики 2019-nCoV; противоопухолевая активность; действие также против мутировавшего вируса.

4.WO/2022/133497NUTRACEUTICAL COMPOUNDS USEFUL IN THE TREATMENT OF CORONAVIRUS DISEASE
WO 23.06.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/073019 Applicant SKYMOUNT MEDICAL US INC. Inventor BESS, Adam
The present disclosure relates to use of and a method of administering a formulation that comprises a combination of at least two compounds selected from the group consisting of: levomenol, a ginseng extract, ascorbic acid; adenine derivatives (Adenosine; NAD+/NADH); ginkgolides such as ginkgolide A; and vitamin E; for treating one or more symptoms of a SARS-CoV-2 infection and for ameliorating symptoms that may persist following a SARS-CoV-2 infection.
5.WO/2022/133137METHOD FOR RAPIDLY AND ACCURATELY DETECTING SARS-CoV-2 NUCLEIC ACID
WO 23.06.2022
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No PCT/US2021/063898 Applicant TUMI GENOMICS Inventor SALDI, Tassa K.
Methods and a kit for detection of genetic material from SARS-CoV-2 that combines reverse transcription loop-mediated isothermal amplification (RT-LAMP) technology with specific oligonucleotide primers, fluorophore-labeled oligonucleotides, quencher technology, buffer components, enzymes, and enzyme ratios chosen to minimize false positive and false negative results, are described. The method includes internal positive control targeting sequences, allowing more certain interpretation of the results. The reaction can be performed at a single elevated temperature, can be completed in 1-2 hours, and the results can readily be interpreted by visually observing the fluorescence color of the reaction using ultraviolet light.
6.WO/2022/127825VACCINE COMPOSITION FOR NOVEL CORONAVIRUS INFECTION
WO 23.06.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2021/138348 Applicant RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTD Inventor HOU, Baidong
The present application relates to a novel coronavirus pathogen-like antigen (PLA) vaccine, a preparation method therefor and an application thereof. The PLA vaccine consists of structurally-modified Escherichia coli virus-like particles (VLPs) and novel coronavirus antigens displayed thereon, and nucleic acid is encapsulated inside of the VLPs. The novel coronavirus PLA vaccine of the present invention formed by passing through modifications effectively prevents the aggregation or precipitation of particles, facilitating the production of the vaccine and ensuring the stability of vaccine efficacy; in addition, relative to conventional vaccines which require additionally adding an additional adjuvant, the PLA-SARS-CoV2 vaccine of the present invention is capable of inducing a significantly higher level of specific antibodies and neutralizing antibodies, having a significantly higher efficacy in challenge tests relative to conventional vaccines.
7.WO/2022/132887HUMAN MONOCLONAL ANTIBODIES TARGETING THE SARS-COV-2 SPIKE PROTEIN
WO 23.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/063493 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor GOLLIHAR, Jimmy, Dale
Provided herein are antibodies and antibody fragments that bind to SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein-targeting antibody.
8.WO/2022/126239COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITY
WO 23.06.2022
Int.Class A61K 47/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Appl.No PCT/CA2021/051543 Applicant DEFENCE THERAPEUTICS INC. Inventor BEAUDOIN, Simon
Covalently modified polypeptide antigens having improved immunogenicity and/or stability, as well as compositions, cells, and methods relating thereto, are described herein. Polypeptide antigens are covalently conjugated to a one or more of steroid acid moieties to improve their stability and/or to trigger improved cellular immunity, or improved cellular and humoral immunity, against the antigen upon administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endocytosis and/or endosomal escape of endosomally trapped cargoes by potentiating enzymatic cleavage of sphingomyelin to ceramide within endosomal membranes. The steroid acid moieties may be pre-conjugated to a peptide, and the steroid acid-peptide moiety subsequently conjugated to the polypeptide antigen. The peptide may comprise one or more domains that impart an additional functionality to the modified polypeptide antigen.
9.0002774333RECOMBINANT PLASMID pET-GST-3CL-GPG PROVIDING SYNTHESIS OF SARS-CoV-2 3CL PROTEASE IN E. COLI CELLS IN SOLUBLE FORM
RU 17.06.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2021139297 Applicant Inventor Щербаков Дмитрий Николаевич (RU)
FIELD: biotechnology. SUBSTANCE: invention relates to biotechnology. A recombinant plasmid pET-GST-3CL-GPG is described, which provides the synthesis of SARS-CoV-2 3CL protease in E. coli cells in a soluble form, having the nucleotide sequence of SEQ ID NO: 2. The plasmid has a map shown in Fig. 1 and contains the following elements: AmpR promoter; a genetic marker that determines ampicillin resistance of E. coli bacteria cells transformed with the recombinant AmpR plasmid; origin of replication site ori; lactose repressor lacI; DNA-binding protein that inhibits the expression of E. coli genes and ensures the expression of the target recombinant 3CL-GPG-6His protein after the addition of an isopropyl-β-D-1-thiogalactopyranoside (IPTG) inducer; lacI promoter; the T7 phage promoter, which ensures the expression of the GST-3CL-GPG gene sequence in E. coli cells; lac operator; RBS; gene GST-glutathione-S-transferase from Scihistosoma japonicum; Pep - region encoding the GSTSAVLQ peptide; the SARS-CoV-2 chimeric 3CL gene also including the GPG and 6His sequence, having the nucleotide sequence of SEQ ID NO: 1, and encoding the synthesis of the 3CL-GPG-6His protease with the amino acid sequence of SEQ ID NO: 3; T7 terminator. EFFECT: invention can be used in biotechnology to obtain the 3CL enzyme, which is the main protease of SARS-CoV-2. This ensures the synthesis and transport of the chimeric variant of the 3CL protein into the periplasmic space of E. coli in a soluble form. 1 cl, 3 dwg, 1 tbl, 5 ex
10.WO/2022/122036IMMUNOGEN AND PHARMACEUTICAL COMPOSITION FOR SARS-COV-2 VIRUS, AND USE THEREOF
WO 16.06.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2021/137244 Applicant BRAVOVAX CO., LTD Inventor MU, Ting
Disclosed in the present application are an immunogen and a pharmaceutical composition for SARS-CoV-2 virus, and the use thereof. The immunogen comprises at least one of a PreS protein or a full-length S protein, or the immunogen comprises a plurality of structural proteins capable of being assembled to form a SARS-CoV-2 virus-like particle. The immunogen can be used for preparing a vaccine and/or a drug, and has the advantages of a high safety, an ideal immune effect and a long immune persistence.